Abstract: A kit of parts and methods for determining the presence and quantity of one or more therapeutic monoclonal antibody drugs and/or therapeutic monoclonal antibody inhibitor drug antibodies in a biological sample, the method including providing a reaction liquid comprising the sample, a first conjugate with the target of the therapeutic monoclonal antibody and a first conjugated moiety and a second conjugate with the target of the therapeutic monoclonal antibody and a second conjugated moiety, followed by detecting the change in spectrophotometric signal when the complex between the therapeutic monoclonal antibody drug, the first conjugate and a the second conjugate forms.

Abstract: The present invention relates to a kit of parts and methods for determining the presence and quantity of one or more TNF-? inhibitor drugs and/or anti-TNF-? inhibitor drug antibodies in one or more biological samples each comprising less than 200 ?l, the method comprising the steps of providing a reaction liquid comprising the sample, a first TNF-? conjugate comprising TNF-? and a first conjugated moiety and a second TNF-? conjugate comprising TNF-? and a second conjugated moiety, said second moiety being capable of generating or ameliorating a detectable signal in the presence of a molecular complex comprising a TNF-? inhibitor, followed by detecting the change in signal when the complex between the TNF-? inhibitor drug, the first TNF-? conjugate and a the second TNF-? conjugate forms.

Abstract: Methods and kits-of-parts for determining the quantity of HbA1c relative to the concentration of haemoglobin in a blood sample which includes less than 200 ?l of blood, the method including the steps of adding the fluorophore to the sample and measuring the fluorescence at one or more time points within the time interval, at which the change in fluorescence over time is >0, followed by measurements of haemoglobin by adding a haemoglobin-binding agent and measuring the change in transmission at approximately 570 nm and comparing the obtained results with an internal standard.

Abstract: The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and/or preventing infections and/or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and/or preventing obesity and related diseases, or treating and/or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles.